Login to Your Account

Prosensa Holding Hops Over the Pond for Nasdaq Debut

By Catherine Shaffer
Staff Writer

Friday, June 28, 2013

Prosensa Holding B.V., of Leiden, the Netherlands, became the first European biotech company in 10 years to file for its initial public offering (IPO) on the Nasdaq to support development of its products for Duchenne's muscular dystrophy and other programs. It plans to raise about $78 million.

Prosensa's product pipeline is based on RNA-modulation, focusing on rare neuromuscular and neurodegenerative disorders with large unmet medical need.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription